AXIM BIOTECHNOLOGIES, INC. (AXIM)

0.00USD +33.33% (+0.00)

Over 1M: +33.3%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

0 0 0.01
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '23 — Operating Cash Flow: -264.5K Q3 '23 — Net Income: 328.5K Q4 '23 — Operating Cash Flow: 19.6K Q4 '23 — Free Cash Flow: 19.6K Q4 '23 — Net Income: -1.9M Q1 '24 — Operating Cash Flow: -252.5K Q1 '24 — Free Cash Flow: -255.3K Q1 '24 — Net Income: -292.3K Q2 '24 — Operating Cash Flow: -261.5K Q2 '24 — Net Income: -2.3M -1.8M -1.2M -600K 0 600K
Q3 '23 Q4 '23 Q1 '24 Q2 '24
Operating Cash Flow Free Cash Flow Net Income

Figures as at 2024-06-30, reported in USD. The newest fact in the filings is dated 2024-06-30, 792 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 98.7%
OE margin -915.8%
Oper. margin -2490.3%
Accruals -90.6%
Gross margin 98.1%
Asset turnover 0.025×
EBITDA margin -2027.9%
FCF margin -817.0%
OCF margin -817.0%
ROA -110.9%
Capex / sales —
OCF / EBIT —
Profit margin —
ROCE —
ROE —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.8
EV/Sales 85.8×
EV/OE -9.4×
FCF yield -39.7%
P/C 316.7×
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/B —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

4.5
RPO / sales 2.5×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

1.2
ND/EBITDA -0.76
Current ratio 0.0032×
Interest cover -11.0×
Cash / Debt 0.001×
F-score 3.0 pts
Quick ratio 2.3e-05×
Cash runway —
Debt / Eq —
Debt payback —
Equity / Assets —
Net debt / Eq —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

6.5
Sales/sh Y/Y +254.6%
Sales CAGR 4Y -52.8%
Sales Q/Q +76.0%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Shares change —

3 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.